

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 16, 2013

Sucampo Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-33609

30-0520478

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

4520 East-West Highway, 3rd Floor
Bethesda, Maryland

20814

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (301) 961-3400

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure.

During July 16-17, 2013, Sucampo Pharmaceuticals, Inc. ("Company") will make corporate update presentations at one-on-one meetings with investors in Minneapolis, Minnesota and Chicago, Illinois. All meetings will include modifications to 4 slides from those slides filed on Form 8K dated June 26, 2013. The additional slides are being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 The modifications of the 4 slides to the corporate update presentation slides dated July 16, 2013.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SUCAMPO PHARMACEUTICALS, INC.

Date: July 16, 2013


By: /s/ Thomas J. Knapp

Name: Thomas J. Knapp

Title: EVP, Chief Legal Officer and
Corporate Secretary

Unique Considerations for Glaucoma Treatment in Elderly Patients

- **More than 40M Americans are ≥ 65 years of age²²**
 - Age is an independent risk factor for glaucoma¹⁸
- **Susceptibility to the systemic adverse effect of glaucoma medications increases with age – and the aging population is growing²³**



See References 18,22-23; for chart see Reference 22,24

RESCULA Launch Update

- **Positive feedback and significant progress**

- Efforts focused on ophthalmologists and optometrists
- More than 25,000 calls have already been made
- Over 86,000 samples have been shipped
- Expect sales to increase in 2H



- **Aggressively pursuing managed care coverage for RESCULA**

- Over 66% of scripts have been approved
- Actively negotiating with all the major health plans and PBMs

- **Route to Savings™: Committed to Patient Access**

- 33% of RESCULA TRxs going through RTS Program
- Commercial co-pay reductions seen from \$55 - \$18

RESCULA
(Uroprostane isopropyl ophthalmic solution) 0.15%

RESCULA ROUTE TO SAVINGS® CARD
Pay-No-More-Than \$20*
up to \$100.00 off per prescription.

Call 1-888-838-9914 to determine your eligibility and activate your card. Once activated, give this card to your pharmacist, along with a valid prescription from your physician.

RxBIN#	PCN#	GROUP#	IDENTIFICATION#
015251	PRX2000	RES01	RE011012018

www.RESCULA.com
EXP DATE: 06/30/2014

SUCAMPO

Key Facts

Trading Symbol	SCMP (NASDAQ)
Corporate Headquarters	Bethesda, MD
Stock Price (07-12-13), 52-Week Range	\$6.99, \$10.48 to \$3.78
Shares Outstanding (07-12-13)	42.5M (1 class of common stock)
Daily Volume (90-day average)	249,250
Market Capitalization (07-12-13)	\$296.9M
Debt (03-31-13)	\$62.5M
Cash & Equivalents (03-31-13)	\$95.8M
Enterprise Value (07-12-13)	\$263.5M
Full-time Employees (06-30-13)	115
Fiscal Year Ends	December 31
Accounting Firm	PricewaterhouseCoopers LLP

References (cont'd)

22. Based on US Census Bureau THE NEXT FOUR DECADES The Older Population in the United States: 2010 to 2050 (May 2010)
23. Kaiserman I et al. Topical beta blockers in asthmatic patients-is it safe? *Curr Eye Res.* 2009 Jul;34(7):517-22.
24. Based on US Census Bureau data from May 2010 and November 2011 The Older Population: 2010 (November 2011)
25. Gottfredsdottir MS et al. Physicians' guide to interactions between glaucoma and systemic medications. *J Glaucoma.* 1997 Dec;6(6):377-83.
26. Based on Dec 2011- Nov 2012 MATTY IMS NPA data
27. RESCULA CVA
28. Joswick et al. *Digestive Disease Week, 2012*
29. AMITIZA Package Insert

The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG.

AMITIZA is a registered trademark of Sucampo AG.

RESCULA is a registered trademark of R-Tech Ueno, Ltd.